Abstract
The article presents the results of clinical studies aimed at confirming information previously obtained in the laboratory about the possibility of using triterpenoid 3ß,28-di-О-isonicotinate betulin (bisizonicotinoate betulin) as a hepatoprotective agent when included in specific and symptomatic therapy. At the same time, it has been proven that the inclusion of betulin bisizonicotinoate in pharmacotherapy and its administration for 7 days, once a day, inside at a dose of 25 mg/kg, exceeds the hepatoprotective effect of karsil with the same dose regime. For example, a new treatment regimen for equine piroplasmosis has been recommended, and a new highly effective remedy, betulin bisizonicotinoate, has been proposed for its use as a means of «pharmacological cover» while prescribing drugs that can cause or aggravate liver pathology.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
